AMERICAN HEADACHE SOCIETY

Due to the COVID-19 pandemic, the 63rd American Headache Society Annual Scientific Meeting was held in a fully virtual format from June 03-06.

Due to the COVID-19 pandemic, the 62nd AHS Congress was a Virtual Congress. This site enables you to access the presentations that have been presented at the AHS virtual meeting

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

JUNE 3-6 | Virtual

JUNE 13 | Virtual

American Headache Society

View the list of presentations

For more information please visit:
63rd American Headache Society Annual Scientific Meeting


Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the post marketing setting

Dodick D, et al; Oral Presentation: IOR-08

Erenumab versus topiramate for the prevention of migraine: Results of a randomized active-controlled double-dummy trial (HER-MES)

Reuter U, et al; ePoster: P223LB

Effects of erenumab on non-pain symptoms in patients with chronic migraine

Tepper SJ ,et al; ePoster: P-171

Efficacy and safety of erenumab in patients with episodic migraine in East Asia: Taiwan and Korea subpopulation analysis of the EMPOwER study

Wang SJ, et al; ePoster: P-188

Changes in blood pressure category with erenumab: A pooled analysis of phase 2 and phase 3 clinical trials

Dodick DW, et al; ePoster: P-202

Evaluation of ischemic cardiovascular and cerebrovascular adverse events by 10-year cardiovascular risk score in patients with migraine treated with erenumab

Kudrow D, et al; ePoster: P-205

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study

Ashina M, et al; ePoster: P-206

Efficacy of erenumab in chronic migraine (CM) patients with acute headache medication overuse (MO) headache: a post hoc analysis assessing outcomes using different definitions of remission

Tepper, S.J. (2020). Efficacy of Erenumab in Chronic Migraine (CM) Patients With Acute Headache Medication Overuse (MO): A Post Hoc Analysis Assessing Outcomes Using Different Definitions of Remission. Headache, 60;S1, 1–207. Pg. 105

Beyond Frequency Alone – Exploring What Meaningful Improvement Means in the Treatment of Migraine: Focus Groups in Patients and Health Care Providers

Sacco, P. (2020). Beyond Frequency Alone- Exploring What Meaningful Improvements Means in the Treatment of Migraine: Focus Groups in Patients and Health Care Providers. Headache, 60;S1, 1–207. Pg. 130

Cardiovascular safety of erenumab in patients with migraine and aura

Ashina, M. (2020). Cardiovascular Safety of Erenumab in Patients with Migraine and Aura. Headache, 60;S1, 1–207. Pg. 101

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

Starling, A.J. (2020). Benefit of Migraine Prevention with Erenumab in Patients Receiv-ing Standard-of-care Acute Treatment. Headache, 60;S1, 1–207. Pg. 101

Effect of erenumab on monthly migraine days and monthly migraine attacks in patients with episodic migraine

Tfelt-Hansen, P. (2020). Effect of erenumab on monthly migraine days and monthly migraine attacks in patients with episodic migraine. Headache, 60;S1, 1–207. Pg. 101

Effects of erenumab on patient-reported outcomes in a subgroup of patients with episodic migraine and severe functional impairment

Lipton, R.B. (2020). Effects of Erenumab on Patient-Reported Outcomes in a Sub-group of Patients With Episodic Migraine and Severe Functional Impairment. Headache, 60;S1,1–207. Pg. 104

Sustained efficacy and safety of erenumab in patients with episodic migraine who failed 2–4 prior preventive treatments: 2-year results of the LIBERTY open-label extension study

Reuter, U. (2020). Sustained Efficacy and Safety of Erenumab in Patients With Episodic Migraine Who Failed 2-4 Prior Preventive Treatments: 2-Year Interim Results of the LIBERTY Open-label Extension Study. Headache, 60;S1,1–207. Pg. 96
Erenumab is co-developed by Novartis and Amgen
Cookie Settings
© Copyright 2021 Novartis Pharma AG